Dr. Christopher Ryan is a clinical researcher whose work focuses on testing new agents for renal carcinoma and sarcomas. He is particularly interested in clinical trial design and novel endpoints. He is currently studying the utility of dynamic contrast enhanced MRI data as a biomarker for activity of novel agents in the treatment of soft tissue sarcomas. His clinical practice is centered around an active trial portfolio.
Dr. Christopher W. Ryan, MD